[Federal Register Volume 62, Number 115 (Monday, June 16, 1997)]
[Notices]
[Page 32616]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-15758]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has made a final finding of scientific misconduct in the
following case:
Fugang Li, Ph.D., University of Oklahoma Health Sciences Center:
Based upon a report from the University of Oklahoma, information
obtained by the Office of Research Integrity (ORI) during its oversight
review, and Dr. Li's own admission, ORI found that Dr. Li, a former
postdoctoral fellow in the Department of Biochemistry and Molecular
Biology, University of Oklahoma Health Sciences Center, engaged in
scientific misconduct by fabricating and falsifying data in conducting
and reporting research supported by a grant from the National Heart,
Lung and Blood Institute (NHLBI), National Institutes of Health (NIH).
Specifically, Dr. Li fabricated and falsified data in a study
involving the characterization of glycoprotein binding to P-selectin on
the surface of human leukocytes. The questioned data were included in a
manuscript that was withdrawn prior to publication.
Dr. Li has accepted the ORI finding and has entered into a
Voluntary Exclusion Agreement with ORI in which he has voluntarily
agreed to exclude himself, for the three (3) year period beginning June
3, 1997, from:
(1) Any contracting or subcontracting with any agency of the United
States Government and from eligibility for, or involvement in,
nonprocurement transactions (e.g., grants and cooperative agreements)
of the United States Government as defined in 45 CFR Part 76 (debarment
Regulations); and
(2) Serving in any advisory capacity to the Public Health Service
(PHS), including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.
No scientific publications were required to be corrected as part of
this Agreement.
FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research
Investigations, Office of Research Integrity, 5515 Security Lane, Suite
700, Rockville, MD 20852, (301) 443-5330.
Chris B. Pascal,
Acting Director, Office of Research Integrity.
[FR Doc. 97-15758 Filed 6-13-97; 8:45 am]
BILLING CODE 4160-17-P
